SCHEMBL1359293

SCHEMBL1359293

COc1ccc(F)c(Cl)c1C(C)c1c[nH]c2ncc(Br)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.43
KIT P10721 8/20 0.39
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
DYRK1A Q13627 4/20 0.36
JAK2 O60674 2/20 0.36
JAK3 P52333 2/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359186 1.00 MET (0.43) METKITHDAC3HDAC4HDAC1
SCHEMBL1357897 1.00 MET (0.43) METKITHDAC3HDAC4HDAC1
SCHEMBL1359403 0.91 MET (0.42) METKITHDAC3HDAC4HDAC1
SCHEMBL1359146 0.91 MET (0.42) METKITHDAC3HDAC4HDAC1
SCHEMBL1357571 0.91 MET (0.42) METKITHDAC3HDAC4HDAC1
SCHEMBL1357872 0.89 MET (0.40) METKITHDAC3HDAC4HDAC1
SCHEMBL1358491 0.87 MET (0.48) METKITHDAC3HDAC4HDAC1
SCHEMBL1357809 0.87 MET (0.48) METKITHDAC3HDAC4HDAC1
SCHEMBL1359421 0.87 MET (0.48) METKITHDAC3HDAC4HDAC1
SCHEMBL1358010 0.85 MET (0.40) METHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2569314-B1 FUSED BICYCLIC KINASE INHIBITORS OSI PHARMACEUTICALS LLC (US) 2016-09-07 EP disclosed
US-20130253197-A1 FUSED BICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, LLC (US) 2013-09-26 US disclosed
US-8445510-B2 Fused bicyclic kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-05-21 US disclosed
US-20110281888-A1 Fused Bicyclic Kinase Inhibitors OSI Pharmaceuticals, LLC 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281888-A1 Fused Bicyclic Kinase Inhibitors ALK, RET, MET MET 3/4885KIT 454/4885HDAC3 568/4885
US-20130253197-A1 FUSED BICYCLIC KINASE INHIBITORS ALK, RET, MET MET 3/4885KIT 454/4885HDAC3 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.